A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Title

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Lead sponsor

National Cancer Institute (NCI)

Phase

Phase 1

Overall status

Completed

Start date

August 31, 2009

Completion date

-Not reported

Enrollment

20 (actual)

Sites

6

childhood burkitt lymphoma, childhood central nervous system choriocarcinoma, childhood central nervous system germ cell tumor, childhood central nervous system germinoma, childhood central nervous system mixed germ cell tumor, childhood central nervous system teratoma, childhood central nervous system yolk sac tumor, childhood choroid plexus tumor, childhood craniopharyngioma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, childhood medulloepithelioma, childhood meningioma, childhood mixed glioma, childhood nasal type extranodal nk/t-cell lymphoma, childhood oligodendroglioma, recurrent childhood anaplastic large cell lymphoma, recurrent childhood brain stem glioma, recurrent childhood central nervous system embryonal tumor, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood ependymoma, recurrent childhood grade iii lymphomatoid granulomatosis, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood malignant germ cell tumor, recurrent childhood medulloblastoma, recurrent childhood pineoblastoma, recurrent childhood small noncleaved cell lymphoma, recurrent childhood subependymal giant cell astrocytoma, recurrent childhood supratentorial primitive neuroectodermal tumor, recurrent childhood visual pathway and hypothalamic glioma, recurrent childhood visual pathway glioma, recurrent/refractory childhood hodgkin lymphoma, unspecified childhood solid tumor, protocol specific